BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31410542)

  • 1. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.
    Wenter V; Jellinek A; Unterrainer M; Ahmaddy F; Lehner S; Albert NL; Bartenstein P; Knösel T; Spitzweg C; Ilhan H; Todica A
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2526-2535. PubMed ID: 31410542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas.
    Amouri W; Charfeddine S; Charfi S; Jardak I; Boudawara T; Guermazi F
    Nucl Med Commun; 2019 Sep; 40(9):888-893. PubMed ID: 31343615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls.
    Carr AA; Yen TWF; Ortiz DI; Hunt BC; Fareau G; Massey BL; Campbell BH; Doffek KL; Evans DB; Wang TS
    Thyroid; 2018 Nov; 28(11):1462-1467. PubMed ID: 30215297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma.
    Wenter V; Albert NL; Unterrainer M; Ahmaddy F; Ilhan H; Jellinek A; Knösel T; Bartenstein P; Spitzweg C; Lehner S; Todica A
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):449-460. PubMed ID: 32683470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis.
    Ahn J; Jin M; Song E; Jeon MJ; Kim TY; Ryu JS; Kim WB; Shong YK; Han JM; Kim WG
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):830-837. PubMed ID: 33202517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic concepts and long-term outcome in thyroid gland carcinoma].
    Linder R; Fuhrmann J; Hammerschmidt D
    Zentralbl Chir; 1996; 121(6):459-64. PubMed ID: 8767331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma.
    Kim M; Han M; Jeon MJ; Kim WG; Kim IJ; Ryu JS; Kim WB; Shong YK; Kim TY; Kim BH
    Clin Endocrinol (Oxf); 2019 Sep; 91(3):449-455. PubMed ID: 31102417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
    Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
    Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
    Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.
    Zhou C; Duan D; Liu S
    Technol Cancer Res Treat; 2021; 20():15330338211027910. PubMed ID: 34191658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.